Company Announcements

• Flatiron’s research at this year’s conference highlights the ability of scalable, high-quality real-world oncology data and novel rigorous approaches for health outcomes research to support both research and regulatory use cases.

NEW YORK--(BUSINESS WIRE)--Apr. 29, 2025-- Flatiron Health today announced its presence at ISPOR—The Professional Society for Health Economics and Outcomes Research 2025 Conference, set to take place May 13-16 in Montreal, QC, Canada. Flatiron’s real-world data is featured across 15+ pieces of research to be presented at the conference, including eight Flatiron authored research posters. Additionally, Flatiron will participate in a panel discussion on the role of real-world evidence in precision medicine, including how real-world data can be leveraged across international borders to inform regulatory and reimbursement decisions within diverse healthcare systems.

“At this year’s ISPOR, Flatiron scientists are using high-quality real-world data to validate novel methodologies that will shape the future of evidence generation and health outcomes research in oncology,” said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. “Leveraging innovative AI and machine learning, Flatiron is expanding the utility of global real-world evidence in regulatory decision-making and across a growing range of oncology use cases at an unprecedented scale.”

Highlights include:

• a poster presentation validating the use of ML to extract real-world response from unstructured data in the electronic health records (EHR), offering a scalable and efficient method for generating high-quality oncology real-world data
• a poster presentation highlighting the acceptance of real-world evidence by the US Food and Drug Administration and the European Medicines Agency, underscoring its potential to complement traditional clinical trial data
• a poster presentation introducing the Flatiron Health Japan Breast Cancer dataset, a novel, de-identified real-world database derived from structured and unstructured data collected from routine oncology care and stored within EHR systems in Japan

Schedule a meeting with Flatiron Health at ISPOR 2025, and learn more about our abstracts and events, including workshops and panels.

Follow Flatiron Health on X and LinkedIn for more updates from #ISPORAnnual and visit us in person at Booth #601.

Poster Discussions and Presentations
Leveraging Machine Learning to Assess the Association of Rash and Survival in Patients With Advanced NSCLC
Qianyu Yuan, Aaron Dolor, Yunzhi Qian, Doug Donnelly, Melissa Estevez, Yulia Kuznetsova, Nisha Singh, Prakirthi Yerram
Poster Session 1
Poster Code: MSR24

Using Regression Discontinuity in Time Design for Real-World Comparative Effectiveness: A Case Study for the Second-Line Use of Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Author Affiliations: Flatiron Health, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado School of Public Health
Nai-Chia Chen, Antal Zemplenyi, Blythe Adamson, Alex M. Kaizer, Cindy O’Bryant, R. Brett McQueen, Kelly E. Anderson
Poster Session 3
Poster Code: MSR87

Performance Assessment and Validation of Real-World Response Data Generated Using a Deep Learning-Based Natural Language Processing Model Across Multiple Solid Tumors
Kelly Magee, Qianyu Yuan, Auriane Blarre, Aaron Cohen, Aaron Dolor, Konstantin Krismer, Tori Williams, Cherie Zhang
Poster Session 5
Poster Code: MSR142

From Data to Decisions: The Role of Real-World Evidence in Recent Multiple Myeloma Drug Approvals in the US and EU
Mamta Parikh, Peter McMahon, Susan Eng, Freda Boateng, Youssef Ghazi, Kerstin Schmidt, Michelle Brockman, Mitch Sierecki
Poster Session 5
Poster Code: HPR136

Advancing Breast Cancer Research in Japan Using EHR-Derived Real-World Data
Blythe Adamson, Dionne Ng, Harlan Pittel, Arun Sujenthiran, Eri Tajima
Poster Session 5
Poster Code: RWD143

Patient Characteristics and Treatment Patterns in Extensive-Stage Small Cell Lung Cancer
Author Affiliations: Flatiron Health, Tennessee Oncology, Jazz Pharmaceuticals
Wade Iams, Taavy Miller, Samantha Reiss, Navit Naveh, Badri Rengarajan, Amy Nguyen, Kristin J. Moore, Xiaozhou Fan
Poster Session 5
Poster Code: HSD69

Augmenting Race and Ethnicity in a Real-World Oncology Cohort Using the Bayesian Improved Surname Geocoding Methodology
Gene Ho, Philani Mpofu, Olive Mbah, Cleo Ryals
Poster Session 5
Poster Code: MSR136

Analytical Approaches to Estimate Medication Persistence From Electronic Health Record Data: A Study of Tyrosine Kinase Inhibitors in Patients With Epidermal Growth Factor Receptor–Positive Advanced Non–Small Cell Lung Cancer
Xinye Li, Brooke Jarrett, Brendan Kerr, Nate Wade, Patrick Ward, Tony Proli
Poster Session 5
Poster Code: MSR157

About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250429420465/en/

Nina Toor
press@flatiron.com

Source: Flatiron Health